Study Protocol
Efficacy of the BioWick® SureLock® Implant for the 
Reattachment of Soft Tissue to Bone in Subjects              
Undergoing Rotator Cuff Repairs 
June 22, 2020
[STUDY_ID_REMOVED]
BioWick® SureLock® Implant  Protocol No.  CAY -001 
Confidential and Proprietary  1  Version 2. 3 June 22, 2020  CAYENNE MEDICAL , INC., A ZIMMER BIOMET COMPANY  
CLINICAL RESEARCH PROTOCOL  
Effic
acy of the BioWick® SureLock® Implant for the Reattachment of Soft Tissue to 
Bone in Subjects Undergoing Rotator Cuff Repairs  
PROTOCOL NUMBER : CAY-001 
Date of Original Protocol: 09/19/2016  
Version  No.: 2.3 
Principal Investigator : Multic enter 
Sponsor : Cayenne Medical, Inc., a Zimmer Biomet company  
This c onfidential information about the  device is pro vided for the exclusive use of the investigator(s) and 
is subject to amendments, updates, edits and/ or recall at any time.  The information in this document may 
not be disclosed unless federal or state law or regulations require such disclosure.  
BioWick® SureLock® Implant  Protocol No.  CAY -001 
Confidential and Proprietary  2  Version 2. 3 June 22, 2020  TABLE OF CONTENTS  
Page 
1.CONTACTS  ............................................................................................................................ 5 
2.SPONSOR  SIGNATURE  ........................................................................................................ 5 
3.INVESTIGATOR  SIGNATURE  ............................................................................................. 6 
4.DISCLOSURE  STATEMENT  ................................................................................................ 7 
4.1 RESTRICTED DISTRIBUTION OF DOCUMENTS  .................................................................. 7 
5.LIST  OF ABBREVIATIONS  .................................................................................................. 8 
6.SYNOPSIS  .............................................................................................................................. 9 
7.SCHEDULE  OF STUDY  EVENTS  ...................................................................................... 12 
8.ETHICAL  CONSIDERATIONS  ........................................................................................... 12 
8.1 INSTITUTIONAL REVIEW BOARD  ................................................................................... 12 
8.2 ETHICAL CONDUCT OF THE STUDY  ............................................................................... 13 
8.3 SUBJECT INFORMATION AND CONSENT  ......................................................................... 13 
8.4 SUBJECT CONFIDENTIALITY  .......................................................................................... 14 
9.INTRODUCTION  ................................................................................................................. 14 
9.1 BACKGROUND AND CURRENT TREATMENT  ................................................................... 14 
9.2 BIOWICK SURELOCK IMPLANT  ..................................................................................... 14 
9.3 RATIONALE FOR THIS STUDY  ........................................................................................ 14 
10.OBJECTIVES  ........................................................................................................................ 15 
10.1  PRIMARY OBJECTIVE  ..................................................................................................... 15 
10.2  SECONDARY OBJECTIVES  .............................................................................................. 15 
11.STUDY  DESIGN ................................................................................................................... 15 
11.1  MEASURES TAKEN TO AVOID BIAS ............................................................................... 15 
11.1.1  RANDOMIZATION  ................................................................................................. 15 
11.1.2  BLINDING  ............................................................................................................ 15 
11.1.3  DESCRIPTION OF THE STUDY DEVICE  .................................................................. 15 
12.SELECTION  OF STUDY  POPULATION  ............................................................................ 16 
12.1  INCLUSION CRITERIA  .................................................................................................... 16 
12.2  EXCLUSION CRITERIA  ................................................................................................... 16 
12.3  SUBJECT WITHDRAWAL  ................................................................................................ 17 
13.STUDY  PROCEDURES  ....................................................................................................... 17 
13.1  SUBJECT IDENTIFICATION  ............................................................................................. 17 
13.2  SUBJECT ENROLLMENT  ................................................................................................. 18 
13.3  SCREEN FAILURES  ......................................................................................................... 18 
13.4  DESCRIPTION OF STUDY PROCEDURES  .......................................................................... 18 
BioWick® SureLock® Implant     
Protocol No.  CAY -001 
 
 
Confidential and Proprietary  
 3      Version 2. 3 June 22, 2020  
 13.4.1  MAGNETIC RESONANCE IMAGING  ....................................................................... 18 
13.4.2  VETERANS RAND  12-I TEM HEALTH SURVEY (VR-12) ...................................... 18 
13.4.3  ASES  RATING SCALE  .......................................................................................... 19 
13.4.4  DELIVERY OF BIOWICK SURELOCK IMPLANT  ..................................................... 19 
13.5  PROCEDURES TO BE CONDUCTED AT EACH STUDY SITE VISIT ..................................... 19 
13.5.1  SCREENING (DAY -28 TO -1) ................................................................................ 19 
13.5.2  ENROLLMENT /VISIT 1 (DAY 1) ............................................................................ 20 
13.5.3  THREE MONTHS /VISIT 2 (DAY 90 ± 14 DAYS) .................................................... 20 
13.5.4  SIX MONTHS /VISIT 3 (DAY 180  ± 30 DAYS) ........................................................ 21 
13.5.5  12 MONTHS /VISIT 4 (DAY 365  ± 30 DAYS) ......................................................... 21 
13.5.6  CORONAVIRUS (COVID-19)  EXPECTATIONS  ...................................................... 21 
14. SAFETY  ................................................................................................................................ 22 
14.1  SAFETY VARIABLES  ...................................................................................................... 22 
15. EFFECTIVENESS  ................................................................................................................ 22 
15.1  EFFECTIVENESS VARIABLES  .......................................................................................... 22 
15.1.1  PRIMARY  ............................................................................................................. 22 
15.1.2  SECONDARY  ........................................................................................................ 22 
16. STATISTICAL  ANALYSIS  AND  PLANNED  ANALYSIS  ................................................ 23 
16.1  INTRODUCTION .............................................................................................................. 23 
16.2  SAMPLE SIZE AND POWER  ............................................................................................. 23 
16.3  ANALYSIS POPULATIONS  ............................................................................................... 23 
16.4  ANALYSIS SUBGROUPS  .................................................................................................. 23 
16.5  STATISTICAL AND ANALYTICAL PLANS  ........................................................................ 23 
16.5.1  PRIMARY ENDPOINT ANALYSES  .......................................................................... 23 
16.5.2  SECONDARY ENDPOINT ANALYSES  ..................................................................... 24 
16.6  HANDLING MISSING DATA ............................................................................................ 24 
16.7  INTERIM ANALYSIS  ....................................................................................................... 24 
17. ADVERSE  EVENTS  AND  SERIOUS  ADVERSE  EVENTS  .............................................. 24 
17.1  SAFETY  ......................................................................................................................... 24 
17.2  DEFINITIONS  ................................................................................................................. 24 
17.3  REPORTING OF SERIOUS ADVERSE EVENTS  ................................................................... 26 
17.4  COLLECTING , RECORDING AND REPORTING ADVERSE EVENTS  .................................... 26 
18. STUDY  SUSPENSION,  TERMINATION,  AND  COMPLETION ...................................... 27 
18.1.1  TERMINATION BY THE SPONSOR  .......................................................................... 27 
18.1.2  TERMINATION BY THE INVESTIGATOR  ................................................................. 28 
19. PROTOCOL  AMENDMENTS  ............................................................................................. 28 
20. QUALITY  CONTROL  AND  ASSURANCE  ........................................................................ 28 
21. DIRECT  ACCESS,  DATA  HANDLING,  AND  RECORD- KEEPING  ................................ 28 
BioWick® SureLock® Implant     
Protocol No.  CAY -001 
 
 
Confidential and Proprietary  
 4      Version 2. 3 June 22, 2020  
 21.1  INVESTIGATOR  .............................................................................................................. 28 
21.2  DATA HANDLING  .......................................................................................................... 29 
21.2.1  GENERAL INSTRUCTIONS FOR DATA COLLECTION  .............................................. 29 
21.2.2  DATA SUBMISSION  .............................................................................................. 29 
21.2.3  QUALITY ASSURANCE OF DATA AND MONITORING  ............................................. 29 
21.2.4  STUDY SITE PERSONNEL CHANGES  ..................................................................... 30 
21.2.5  ADVERSE EVENT REPORTING  .............................................................................. 30 
21.2.6  REVIEW OF SOURCE RECORDS  ............................................................................. 30 
21.2.7  MONITORING OF THE STUDY  ............................................................................... 30 
22. PUBLICATIONS  POLICY  ................................................................................................... 31 
REFERENCES ............................................................................................................................. 32 
 
BioWick® SureLock® Implant  Protocol No.  CAY -001 
Confidential and Proprietary  5  Version 2. 3 June 22, 2020  1. CONTACTS
Contact the following individuals for all other inquiries and information about this study: 
Program Director  
 
[REDACTED] Clinical S tudy Manager 
[REDACTED] 
2. SPON
SOR  SIGNATURE
My signature, in conjunction with the signature of the investigator, confirms the agreement of 
both parties that the clinical stud y will be conducted in accordance with the protocol and 
applicable laws and other regulations including, but not limited to, the ICH Guideline for Good 
Clinical Practice, the US C ode of Federal Regulations, protections for privacy, and generally 
accepted ethical principles for human research such as the Declaration of Helsinki. 
Not
hing in this document is intended to limit the authority of a physician to provide emergency 
medical care.  
 S
ponsor Representative Signature Da
te of Signature  
(DD MMM YYYY)  
____________________________________________________________________ S
ponsor Representative Name and Title (print)  
BioWick® SureLock® Implant  Protocol No.  CAY -001 
Confidential and Proprietary  6  Version 2. 3 June 22, 2020  3. I NVESTIGATOR SIGNATURE
I have read this protocol and agree that it contains all necessary details to carry  out the study as 
described .  I will conduct this protocol as outlined herein, including all statements regarding 
confidentiality .  I will make a reasonable effort to complete the study within the time designated .  
I will provide copies of the protocol and access to all information furnished by the Sponsor to 
study personnel under my supervision.  I will discuss this material with them to ensure that they are fully informed about the test  and the study.  I understand that the study may be terminated or 
enrollment suspended at any time by the Sponsor, with or without cause, or by me if it becomes necessary to protect the interests of the study subjects.  Any supplemental information that may be added to this document is also confidential and proprie tary to Cayenne Medical, Inc., a 
Zimmer Biomet company, and must be kept in confidence in the same manner as the contents of 
this protocol.  
I a
gree to conduct this study in full accordance with all applicable regulations and Good Clinical 
Practice.  
Inve
stigator’s Signature Date of Signature  
(DD MMM YYYY)  
Investigator’s Name (print)  
BioWick® SureLock® Implant     
Protocol No.  CAY -001 
 
 
Confidential and Proprietary  
 7      Version 2. 3 June 22, 2020  
 4. DISCLOSURE STATEMENT  
4.1 Restricted Distribution of Documents   
This document contains information that is confidential and proprietary to Cayenne Medical, 
Inc., a Zimmer Biomet company  This information is being provided solely for the purpose of evaluating and/or conduc ting the clinical trial for Cayenne Medical, Inc.  You may disclose the 
contents of this document only to study personnel under your supervision, IRBs, or authorized representatives of regulatory agencies for this purpose under the condition that they maintain confidentiality .   
 The contents of this document may not be used in any other clinical trial, disclosed to any other person or entity, and/or published without the prior written permission of the Sponsor.  The foregoing shall not apply to disclosure required by any regulations; however, you will give prompt notice to Cayenne Medical, Inc.  of any such disclosure. 
 All other nonpublic information provided by Cayenne Medical, Inc., as well as a ny information 
that may be added to this document, is also co nfidential and proprietary to Cayenne Medical, Inc. 
and must be kept in confidence in the same manner as the contents of this document.  
BioWick® SureLock® Implant     
Protocol No.  CAY -001 
 
 
Confidential and Proprietary  
 8      Version 2. 3 June 22, 2020  
 5. LIST OF ABBREVIATIONS 
Abbreviation  Term  
AE Adverse Event/ Adverse Experience  
CFR  Code of Federal Regulations  
CRA  Clinical Research Associate  
CRF  Case Report Form 
CRO  Contract Research Organization  
DMP  Data Management Plan  
EDC  Electronic Data Capture  
EMG -NCV  Electromyelopathy and Nerve Conduction  Velocity  
FDA  Food and Drug Administration  
GCP  Good Clinical Practice  
HIPAA  Health Insurance Portability and Accountability Act  
ICF Informed Consent Form 
ICH International Conference on Harmonization  
iCRF  Internet Case Report F orm 
IRB Institutional Review Board 
ITT Intent to Treat  
IV Intravenous  
MCS  Mental Component Score  
PC Personal Computer  
PCS Physical Component Score  
PHI Protected Health Information  
PI Principal Investigator  
SAE  Serious Adverse Event  
SAS Statistical Analysis System  
SDV  Source Document V erification  
SOC  Standard of Care  
TEAE  Treatment Emergent Adverse E vent 
UHMWPE  Ultra High Molecular Weight Polyethylene  
UPS United Parcel Service  
USA  or U.S.  United States of America  
USB  Universal Serial Bus  
VAS  Visual Analog Scale  
VR-12 Veterans RAND 12 Item Health Survey  
  
BioWick® SureLock® Implant     
Protocol No.  CAY -001 
 
 
Confidential and Proprietary  
 9      Version 2. 3 June 22, 2020  
 6. SYNOPSIS  
Study Title  Efficacy  of the BioWick® SureLock® Implant for the 
Reattachment of Soft Tissue to Bone in Subjects Undergoing 
Rotator Cuff Repairs  
Sponsor  Cayenne Medical, Inc., a Zimmer Biomet company 
Study Design The study is a prospective , non -randomized, open -label , single -
arm study that includes both preoperative assessments and follow-
up assessments at 3 months, 6 months, and 12 months. 
Clinical Phase   Postmarket   
Number of Sites  Up to ten site s in the U.S. 
Study Duration per 
Subject  Subjects wil l be enrolled in the study for up to 12 months.    
Primary  Objective  The primary objective of this study is to assess survivorship (lack of reoperation/device removal) with the use of the BioWick  
SureLock  implant.  
Secondary Objective  The secondary objectives of this study are :  
• To document the postmarket effectiveness of the BioWick 
SureLock i mplant using range of motion measurements, 
ASES scores, VR -12 scores, and VAS scores, with the 
corresponding assessments made at 3 months, 6 months, and 12 months. 
• To document device safety via device- related adverse 
events reported over the course of the study.  
Primary Endpoint The primary endpoint of this study is the BioWick SureLock 
implant survivorship at 12 months post -operative.  
Secondary Endpoints The secondary endpoints of this study are:  
• Implant survivorship at  visit intervals other than 12 
months  
• VR-12 scores at 3 months, 6 months, and 12 months 
postoperative 
• ASES rating scale at 3 months, 6 months, and 12 
months postoperative 
• VAS pain scores at 3 months, 6 months, and 12 
months postoperative 
• Range of motion (ROM)  at 3 months, 6 months, and 
12 months postoperative 
 
BioWick® SureLock® Implant     
Protocol No.  CAY -001 
 
 
Confidential and Proprietary  
 10      Version 2. 3 June 22, 2020  
 Inclusion Criteria  Inclusion Criteria  
1. Clinical diagnosis of rotator cuff tear which is greater than or 
equal to 1.5 cm and less than or equal to 4.0 cm full thickness 
of either the supraspinatus or infraspinatus determined by MRI 
which has not been previously repaired; 
2. Goutallier Stage 2 or less;  
3. Patte Stage II (mid humeral head retraction);  
4. Tear(s) confirmed intra -operatively by calibrated probe, tears 
measured in both anterior-posterior and medial- lateral planes;  
5. Subject is  skeletally mature at the surgical site;  
6. Subject is able to read and understand the ICF and has voluntarily provided written informed consent.  
Exclusion Criteria  1. Clinical diagnosis of a rotator cuff tear of the subscapularis 
that requires repair (not including debridement); 
2. Conditions which, in the opinion of the Principal Investigator, 
may limit the subject’s ability or willingness to follow post-
operative care or study instructions; 
3. If female, subject is pregnant;  
4. Presence of local or systemic infect ion;  
5. Suprascapular nerve compression requiring release or 
documented by EMG- NCV;  
6. Substance abuse, including tobacco, alcohol, or illicit drugs which, in the investigator’s judgment, could impair healing or 
influence study compliance;  
7. Foreign body sensiti vity. If material sensitivity is suspected, 
testing should be completed prior to device implantation; 
8. Insufficient blood supply or previous infection which may 
hinder the healing process; 
9. Subject conditions including: insufficient quantity or quality of bone or soft tissue, or immature bone where the device may 
impact or disrupt the growth plate;  
10. Subject is a prisoner or member of another vulnerable population; 
11. Cortisone injection within 6 weeks prior to surgical treatment;  
12. Use of immune suppressants or che motherapeutic medications 
within  the last 12 months; 
BioWick® SureLock® Implant     
Protocol No.  CAY -001 
 
 
Confidential and Proprietary  
 11      Version 2. 3 June 22, 2020  
 13. Use of systemic corticosteroids at any daily dose for more 
than 1 month within the last 12 months. 
Safety Evaluation Safety evaluations will be based on the frequency and incidence 
of device related adverse events . 
Planned Sample 
Size A maximum of 71 subjects will be enrolled in the study. 
Statistical Analysis  The following analysis populations will be defined for the study:   
 
Intention to Treat (ITT) Population – The ITT population will consist of all subjects who have signed informed consent, been enrolled in the study, and have had successful placement of the BioWick™ SureLock™ implant. 
 
Safety Population  – The safety population will consist of 
all subjects wh o have signed informed consent, been 
enrolled in the study, and have had a procedure during which BioWick SureLock  implant placement was 
attempted, whether or not placement was successful.  
   
The primary analysis population for all primary and secondary endpoints will be the ITT population.  The primary analysis population for safety will be the safety population.   
Analysis of Primary Endpoint  
Implant survivo rship for each subject will be determined by 
whether the subject undergoes a device 
removal/revision/reoperation of the study device. 
 
 
BioWick® SureLock® Implant     
                          Protocol No.  CAY -001 
  
 
Confidential and Proprietary  
 12           Version 2.3 June 22, 2020  
 7. SCHEDULE OF STUDY EVENTS   
     Table 7.1 Study Flowchart of Scheduled Events   
Event  Screening  
(Day -28 to -1) Enrollment/  
Visit 1  
(Day 1 )1 3 Months/  
Visit 2  
(Day 90 ± 14 
Days)  6 Months/  
Visit 3  
 (Day 180 ± 30 
Days)  12 Months/  
Visit  4 Or Early 
Termination 
Visit2 
 (Day 365 ± 30 
Days)  
Informed Consent  X     
Inclusion/Exclusion Criteria  X X    
Medical History  X     
Physical Exam  X     
Concomitant Medications  X X X X X 
BioWick  SureLock   
Surgical Implantation  X    
Magnetic Resonance Imaging X3     
ASES Rating Scale  X  X X X 
VR-12 Health Survey  X  X X X 
ASES Range of Motion  X  X X X 
Adverse Events  X X X X X 
Subject Completion     X 
 
1 Upon meeting all I/E criteria, subjects will be enrolled on Day 1 after final confirmation of intra -operative I/E criteria.  
2 Assessments to be completed if the subject is an early withdrawal and returns to the clinic for a final visit.  
3 A MRI scan obtained within 6 months of screening may be used to confirm I/E criteria. If a MRI scan is not available 
within this time frame, then a screening MRI scan is required.  
8. ETHICAL CONSIDERATIO NS 
This clinical study is designed to comply with International Conference on Harmonization 
(ICH) Guidance on General Considerations for Clinical Trials (62 FR 66113, 17 Dec 1997),  
Clinical Investigation of M edical D evices for Human S ubjects -- Good C linical P ractice 
(ISO14155:2011), and Good Clinical Practice: Consolidated Guidance (62 FR 25692,09 May 
1997). 
 
8.1 Institutional Review Board  
It is the responsibility of the investigator to obtain the approval of the IRB before the start of 
the study. The IRB must be registered and active with the Office for Human Research 
Protections of the US Department of Health and Human Services. A copy of the approval 
letter along with a roster of IRB members and/or the US Department of Health and Human 
Services Federal Wide Assurance N umber  will be retained as part of the study records. 
During the course of the study, the investigator will provide timely and accurate reports to the 
IRB on  the progress of the study at appropriate intervals (not to exceed 1 year) and at the 
completion of the study. The investigator will notify the IRB of SAEs , protocol deviations or 
other significant s afety findings per IRB guidelines. The study protocol, IC F, advertisements 
(if any), and amendments (if any) will be approved by the IRB in conformance with CFR, 
Title 21 , Part 56 . 
 
BioWick® SureLock® Implant     
                          Protocol No.  CAY -001 
  
 
Confidential and Proprietary  
 13           Version 2.3 June 22, 2020  
 8.2 Ethical Conduct of the Study  
The study will be conducted in full compliance with applicable FDA regulations and ICH 
guidelines for GCP and in accordance with the ethical principles that have their origins in the 
Declaration of Helsinki.  
 
8.3 Subject  Information and Consent  
A copy of the proposed informed consent documents will be submitted to the Sponsor for 
review and approval before submission to the appropriate IRBs. The study will not begin until the documents have been reviewed and approved by the Sponsor and the documents have been approved by the IRBs.   
The ICF shall contain all of the elements of informed consent specified  in the Code of 
Federal Regulations (21 CFR 50.25) and HIPAA authorization. Copies of the regulations 
relating to informed consent and the protection of human subjects in clinical studies are available from the Sponsor.  All potential study subjects will b e given copies of the following before participating in any 
screening procedures:  
• The study ICF; 
• Agreement  for HIPAA Authorization  (if separate from ICF) ; 
• Any specific documentation that may be required by the site’s IRB.  
 
Subjects will have an opportunity to discuss the contents of these forms with study site  staff.  
The study should be thoroughly explained including the purpose of the study, methods, anticipated benefits , and potential hazards prior to obtaining written consent. 
Subject s must understand and voluntarily sign these forms in compliance with 21 CFR , Part  
50, before parti cipating in any study-related procedures. Subject s will be made aware that 
they may withdraw from the s tudy at any time.  
 The subject will be made aware of his/her right to see and copy his/her records related to the study for as long as the investigator has possession of this information. If the subject  
withdraws consent and/or HIPAA authorization, the investigator can no longer disclose health information, unless it is needed to preserve the scientific integrity of the study.   A copy 
of the signed informed consent document will be given to the subjects for their records.  The subjects will also be informed that their medical records ma y be reviewed by the study 
Sponsor or designee, quality assurance auditor, or inspector from FDA or similar foreign authorities. The subjects will be informed that these persons are bound by the same confidentiality obligations as the subject’s physician.  Nothing in these regulations is intended to limit the authority of a physician to provide emergency medical care under applicable regulations. Regulations require that Investigators 
BioWick® SureLock® Implant     
                          Protocol No.  CAY -001 
  
 
Confidential and Proprietary  
 14           Version 2.3 June 22, 2020  
 permit the Sponsor, Sponsor representatives, and appropriate regulatory a gencies to conduct 
inspections and review records pertaining to clinical investigations. 
The delegation of Investigator responsibilities, including obtaining informed consent, must be 
documented in the study records.  
8.4 Subject Confidentiality  
 
The P rincipal Investigator and designees, employees, and agents involved with this study will 
comply with relevant state and federal laws relating to the confidentiality, privacy , and 
security of subject’s PHI . They will only create, maintain, use, or disclose any data that is 
generated by this study or other information disclosed to the P rincipal Investigator or their 
employees or agents during the course of the study to the Sponsor , IRB, FDA, or other 
authorized recipients as appropriate for the execution, ana lysis, review , and reporting of this 
study. Such information shall not be used for any other purposes and will remain confidential. 
Subject records are only to be identified by initials and subject ID numbers. Subject names 
are not to be transmitted on any document to the Sponsor.  
 
9. INTRODUCTION  
9.1 Background and Current Treatment  
Fixation in soft tissues is traditionally achieved by using a solid anchor which has been loaded with non-absorbable sutures, a technique which has proven adequate ly effective but 
which carries the risk of displacement or relocation of the anchor as well as bone loss and/or 
articular damage. Additionally, existing products require manual “tugging” of the anchor in order to achieve deployment, and, in the event that the anchor is not deployed correctly, the anchor may subsequently pull out.   
9.2 BioWick SureLock  Implant  
 
The BioWick  SureLock  implant is a device for shoulder and extremity surgery, constructed 
of Ultra High Molecular Weight Polyethylene Suture. BioWick  SureLock  is uniquely 
designed to minimize these risks by avoiding manual tensioning with an inserter mechanism that ensures that the implant is consistently deployed below the cortex.  
 
9.3 Rationale for This Study  
 
The purpose of this study is to collect postmarket da ta in subjects who receive surgical 
treatment of a full- thickness rotator cuff tear (of at least 1.5 cm) with the BioWick  SureLock  
implant. Both performance and safety data will be collected.         
   
BioWick® SureLock® Implant     
                          Protocol No.  CAY -001 
  
 
Confidential and Proprietary  
 15           Version 2.3 June 22, 2020  
 10. OBJECTIVES  
10.1 Primary  Objective  
The primary objective of this study is to assess survivorship (lack of reoperation/device 
removal) with the use of the BioWick SureLock  implant.  
 
10.2 Secondary  Objective s 
The secondary objectives of this study are:  
• To document the postmarket effectiveness of the BioWick SureLock i mplant using 
ASES scores, VR -12 scores, and VAS scores, with the corresponding assessments 
made at 3 months, 6 months, and 12 months postoperative. 
• To document the postmarket effectiveness o f the BioWick SureLock implant using 
range of motion (ROM) measurements with the corresponding assessments made at 3 
months and 6 months postoperative.  
• To document device safety via device- related adverse events reported over the course 
of the study.  
      
11. STUDY DESIGN  
The study is a prospective, non-randomized, open-label, single- arm, postmarket, multicenter 
study. The schedule of study events list the procedures to be performed in each visit (see Table 7.1).  
11.1 Measures Taken to Avoid Bias 
11.1.1 Randomization 
All subjects enrolled in the study will be treated with the BioWick  SureLock i mplant. As 
there is no comparison arm, there will be no randomization.  
 
11.1.2 Blinding  
As this study is a single -arm study in which all subjects are treated with the BioWick  
SureLock  implant, neither subjects nor investigators will be blinded.      
 11.1.3 Description of  the Study Device  
The BioWick  SureLock  implant is a device constructed of ultra-high molecular weight 
polyethylene suture for use in shoulder and extremity surgery. The BioWick SureLock 
implant eliminates manual tensioning through a unique inserter- controlled deployment 
method that prevents partial deployment as well as displacement or partial deployment of the anchor by consistent deployment of the anchor below the cortex. The inserter is made of surgical grade stainless steel and plastic, and the wick component is made of 85/15 PLGA (L-
lactide-coglucolide ).   
 
BioWick® SureLock® Implant     
                          Protocol No.  CAY -001 
  
 
Confidential and Proprietary  
 16           Version 2.3 June 22, 2020  
 12. SELECTION OF STUDY POPULATION  
Subjects will be recruited from patients requiring rotator cuff repair surgery  or have 
previously had a rotator cuff tear repaired  using the BioWick  SureLock  implant .  
  
12.1 Inclusion Criteria  
Subjects must meet all of the following inclusion criteria to participate in this study:  
Inclusion Criteria  
1. Clinical diagnosis of rotator cuff tear which is greater than or equal to 1.5 cm and less 
than or equal to 4.0 cm full thickness of either the supraspinatus or infraspinatus 
determined by MRI, which has not been previously repaired;  
2. Goutallier Stage 2 or less;  
3. Patte Stage II  (mid humeral head retraction); 
4. Tear(s) confirmed intra -operatively by calibrated probe, tears measured in both 
anterior- posterior and medial -lateral planes;  
5. Subject is  skeletally mature at the surgical site;  
6. Subject is able to read and understand the ICF and has voluntarily provided written informed consent. 
 
12.2 Exclusion Criteria  
Any subject who meets any of the exclusion criteria will be excluded from participation in 
this study: 
1. Clinical diagnosis of a rotator cuff tear of the subscapularis  that requires repair (not 
including debridement); 
2. Conditions which, in the opinion of the Principal Investigator, may limit the subject’s 
ability or willingness to follow post-operative care or study instructions; 
3. If female, subject is pregnant;  
4. Presence of local or systemic infection;  
5. Suprascapular nerve compression requiring release or documented by EMG- NCV;  
6. Substance abuse, including tobacco, alcohol, or illicit drugs which, in the investigator’s judgment,  could impair healing or influence study compl iance;  
7. Foreign body sensitivity. If material sensitivity is suspected, testing should be completed prior to device implantation; 
8. Insufficient blood supply or previous infection which may hinder the healing process; 
9. Subject conditions including: insufficient quantity or quality of bone or soft tissue, or 
immature bone where the device may impact or disrupt the growth plate; 
10. Subject is a prisoner or  member  of another vulnerable population; 
11. Cortisone injection within 6 weeks prior to surgical treatment;  
12. Use o f immune suppressants or  chemotherapeutic medications within the last 12 
months; 
BioWick® SureLock® Implant     
                          Protocol No.  CAY -001 
  
 
Confidential and Proprietary  
 17           Version 2.3 June 22, 2020  
 13. Use of systemic corticosteroids at any daily dose for more than 1 month within the 
last twelve months.  
        
12.3 Subject Withdrawal  
Subjects may discontinue from the study at any time.  A subject may be discontinued from the study for the following me dical or administrative reasons:  
 
• Subject Withdrawal of Consent - Subjects will be free to discontinue from the study at 
any time and for any reason but must notify the study site of their exit from the study.  
• Adverse E vent – If during the procedures the subject suffers an AE that, in the judgment 
of the PI, Sponsor or medical monitor, presents an unacceptable consequence or risk to the subject, the subject will be discontinued from further participation in the study. 
• Lost to Follow Up – Subjects discontinue from the study without notifying the study site.  
• Serious P rotocol Violation – If , during enrollment in the study, the subject fails to 
follow, violates or refuses to participate in any of the procedures described in the protocol 
then the subject will be discontinued from the study at the discretion of the Sponsor.  If, at any point during the study, a subject is determined to have been erroneously enrolled into the study, the subject will be discontinued from the study due to protocol violation.  
• Other - If the above reasons are not applicable, “Other” will be sele cted as the option and 
the appropriate reason for subject withdrawal provided.  
 
For subjects who discontinue or are withdrawn from the study for any reason, the PI will notify the Sponsor and attempt to recover the following: 
 
• AE occurrences since the last  visit to the study site  
• Concomitant medication usage since the last visit to the study site  
If the subject is withdrawn at a study visit, the procedures for an early termination visit will 
be conducted to assess their continued well -being.   
  
13. STUDY PRO CEDURES   
 13.1 Subject Identification  
Each subject will be assigned a unique subject number. Subject numbers will not be 
reassigned or reused for any reason.  Only their assigned subject number, initials, and date of birth should identify subjects to the Sponsor.  The investigator must maintain a list of potential subjects and enrolled subjects using the Su bject Sc reening/Enrollment Log.  
 Any potential subjects who are pre-screened can be added to the log by recording their screening number and initials only. Those who sign the ICF will be assigned a unique study ID. 
 
BioWick® SureLock® Implant     
                          Protocol No.  CAY -001 
  
 
Confidential and Proprietary  
 18           Version 2.3 June 22, 2020  
 13.2 Subject Enrollment  
Subjects who meet all inclusion and exclusion criteria will be considered eligible for 
enrollment.  S ubjects will be considered enrolled on Day 1 following final confirmation of 
the intra -operative inclusion/exclusion criteria. Hence, subjects who begin a surgical 
procedure may exit the study as a screen failure.   Once enrolled , a subject may only exit the 
study as a withdrawal (not a screen failure). The reason for withdrawal will be documented by the investigator on the Su bject Sc reening/Enrollment Lo g.  
 
13.3 Screen Failures 
Subjects who sign an informed consent form and fail to meet the inclusion and/or exclusion 
criteria are defined as screen failures.  For all screen failures, the investigator will record  the 
reason for the screen failure on the Su bject Sc reening/Enrollment Lo g.  A copy of the log will  
be retained in the investigator's study files.    
13.4 Description of Study Procedures  
Subjects enrolled will follow the study procedures outlined in Section 13.   
 
13.4.1 Magnetic Resonance Imaging  
Magnetic resonance imaging (MRI) of the rotator cuff tear will be obtained during screening 
(baseline) . A screening MRI scan will not be required if a MRI scan was obtained within 6 
months of screening based on a review of the subject’s medical history. All pre -operative 
screening or prior qualifying scans and post-operative study scans should be performed on a 1.5T magnet  or better. Additionally, a standardized imaging protocol will be utilized for all 
images collected as par t of the study procedures.  
 All radiographic images will be read and reviewed by Medical Metrics Inc. to confirm inclusion criteria . 
 
13.4.2 Veterans RAND 12 -Item Health Survey (VR -12) 
The VR-12 is  a 12- item self -administered health survey. The VR-12 consists of eight scales 
which evaluate physical health and mental health.  
 Physical Health Scales:  
• General Health  
• Physical F unctioning 
• Role -Physical  
• Bodily Pain 
 Mental Health Scales:  
• Role -Emotional 
BioWick® SureLock® Implant     
                          Protocol No.  CAY -001 
  
 
Confidential and Proprietary  
 19           Version 2.3 June 22, 2020  
 • Vitality  
• Mental Health  
• Social Functioning 
 
The responses to  the physical health scales will be evaluated to produce the Physical 
Component Score (PCS), and the responses to  the mental health scales will be evaluated to 
produce the Mental Component Score (MCS).  Both the PCS and MCS will be determined for all subjects at screening,  and at 3 months, 6 months, and 12 months  postoperative. 
13.4.3 ASES Rating Scale  
The American Shoulder and Elbow Surgeons (ASES) Functional Questionnaire is an eleven-item self -repor t questionnaire  consisting of ten questions which evaluate function and one 
question that evaluates pain. The function section of the survey yields a score between 0 and 30, with a score of zero indicating maximum disability. VAS Pain Score is included and is measured on a ten point scale, with a maximum pain score of ten. ASES Ratings will be 
determined for all subjects at screening, and at 3 months, 6 months, and 12 months  
postoperative. 
     
13.4.4 Delivery of BioWick SureLock  Implant 
The approved surgical technique will be followed for delivery of the Bio Wick SureLock 
Implant.  The surgical technique will be provided separately. 
 
13.5 Procedures To Be Conducted at Each Study Site Visit  
13.5.1 Screening (Day -28 to -1) 
The screening period of the study will take place up to 28 days prior to enrollment. Subjects 
will visit the study site and receive initial study documents including the ICF. Subjects will be given ample time to review and ask any questions about the clinical trial prior to signing 
informed consent. Once informed consent is obtained, the subject will be screened according 
to inclusion and exclusion criteria.  Site personnel will evaluate the subject’s current pain level using the VAS pain scale.  
Disability and function will be assessed through evaluation of ASES scores, VR-12 scores, and ROM  measurements.   These evaluations will serve as the preoperative baseline scores.  
  
Screening Visit Tasks  
 
• Informed consent 
• Inclusion/e xclusion criteria  
• Assess prior medications  
• Medical history  
• Physical exam  
BioWick® SureLock® Implant     
                          Protocol No.  CAY -001 
  
 
Confidential and Proprietary  
 20           Version 2.3 June 22, 2020  
 • MRI exam  (may be obtained from medical history within previous 6 months) 
• ASES Physician and Patient S cores  
• VR-12 scores 
• Concomitant Medications 
 
13.5.2 Enrollment/Visit 1 (Day 1) 
Subjects who meet all pre -operative inclusion/exclusion criteria will return to the study site  
for their surgical procedure and enrollment into the study. Upon arrival at the site and final confirmation of the pre-operative inclusion/exclusion criteria, the s ubject will be prepped for 
the surgical procedure. Final confirmation of the inclusion/exclusion criteria will be made intra-operatively, at which point subjects will be enrolled in the study if they continue to be 
study- eligible.  
Standard post- operative care will occur for all subjects according to site procedures. The 
subjects will be assessed for any adverse events that have occurred following the placement of the study device  and concomitant medications will be recorded. Pr ior to hospital discharge, 
the site will go over all rehabilitation procedures with the subject per the  rehabilitation 
protocol for the study.    
 
Enrollment/Visit 1 Tasks  
 
• Confirm pre -operative inclusion/e xclusion c riteria  
• Surgical Procedure  
o Confirm intra -operative inclusion/exclusion c riteria  
o Use of BioWick  SureLock implant 
• Assess any AEs  
 
13.5.3 3 Months /Visit 2  (Day 90 ± 14 Days) 
Upon arrival at the clinic, site personnel will  evaluate the subject’s current pain level using 
the ASES.  Disability and function will be assessed through evaluation of ASES scores and 
VR-12 Scores. The subject will be asked about any adverse health events that have occurred since implantation of the device as well as any medications they are taking.   
Visit 2 Tasks  
 
• VAS scores 
• ASES scores  
• VR-12 scores 
• ROM measurements 
• Assess AEs  
• Concomitant m edications 
 
BioWick® SureLock® Implant     
                          Protocol No.  CAY -001 
  
 
Confidential and Proprietary  
 21           Version 2.3 June 22, 2020  
 13.5.4 6 Months /Visit 3 ( Day 180 ± 30 Days)  
Upon arrival at the clinic, site personnel will evaluate the subject’s current pain level using 
the ASES.  Disability and function will be assessed through evaluation of ASES scores, and VR-12 Scores. The subject will be asked about any adverse heal th events that have occurred 
since the last study visit as well as any medications they are taking.  
 
Visit 3  Tasks  
 
• VAS scores 
• ASES scores  
• VR-12 scores 
• ROM measurements 
• Assess AEs 
• Concomitant medications  
 13.5.5 12 Months /Visit 4  (Day 365 ± 30 Days)  
Upon arrival at the clinic, site personnel will evaluate the subject’s current pain level using 
the ASES.  Disability and function will be assessed through evaluation of ASES scores, and VR-12 Scores. The subject will be asked about any adverse health events that have occurred since implantation of the device as well as any medications they are taking.   
Visit 4 Tasks  
 
• VAS scores 
• ASES scores  
• VR-12 scores 
• ROM measurements 
• Assess AEs  
• Concomitant medications  
• Complete Study Completion CRF 
 
After completion of the final procedure required for this visit, the subject’s participation in the study is complete, and the site should fill out the Study Completion Case Report Form (CRF).   
13.5.6 Coronavirus ( COVID-19) Expectations  
If subjects are not allowed at the clinic for visits o r if subjects refuse to come in to the clinic 
due to COVID-19, then the following tasks should take place:  
 
• Subject questionnaires (VAS, ASES, and VR-12) will be  mailed to the subject  for 
completion. These questionnaires should not be completed via phone. If the site does 
not receive a response from the subject, t he site must attempt to contact the subject 
BioWick® SureLock® Implant     
                          Protocol No.  CAY -001 
  
 
Confidential and Proprietary  
 22           Version 2.3 June 22, 2020  
 and/or re- mail the subjec t questionnaires at least three (3) times within the visit 
window before submitting a protocol deviation, unless a response is received.  
• The site will attempt to contact the subject to inquire of adverse events that may have 
occurred and/or been resolved since their last visit. The site is required to perform at least three (3) contact attempts  to obtain this information. These contact attempts must 
be documented in the subject’s study binder. If there is no response by the end of the visit window, a note- to-file (NTF) must be added to the subject ’s study binder 
indicating  new adverse events were not confirmed for the visit.  
• ROM m easurements will not be required ; however, a protocol deviation must be 
submitted.  
• Label protocol deviations as being related to COVID -19, as applicable  
 Please note that these expectations are specifically for COVID-19 situations. If a subject misses a visit unrelated to COVID -19, this section does not apply and a “Missed Visit” 
protocol deviation will be submitted.   
14. SAFETY  
14.1 Safety Variables 
Safety will primarily be assessed through frequency and incidence of adverse events.. 
 
15. EFFECTIVENESS  
15.1 Effectiveness Variables   
15.1.1 Primary  
The primary endpoint of this study is survivorship (lack of reoperation/device removal)  at 12 
months postoperative.    
 
15.1.2 Secondary  
The secondary endpoints of this study are: 
• Implant survivorship at visit intervals other than 12 months  
• VR-12 scores at 3 months, 6 months, and 12 months postoperative 
• ASES rating scale at 3 months, 6 months, and 12 months  postoperative 
• VAS pain scores at 3 months, 6 months, and 12 months postoperative 
• Range of motion (ROM)  at 3 months, 6 months, and 12 months postoperative 
 
The above endpoints based on continuous data will be reported as both raw and change from 
baseline (CFB) results.  
BioWick® SureLock® Implant     
                          Protocol No.  CAY -001 
  
 
Confidential and Proprietary  
 23           Version 2.3 June 22, 2020  
 16. STATISTICAL ANALYSIS  AND PLANNED ANALYSI S  
16.1 Introduction 
This study is a post-marketing, single treatment group, prospective study conducted at up to 
three study centers. The study will be conducted at as many as ten (10) center s in the U.S.  
Subjects will be enrolled in the trial for a period of 12 months.  The objectives of the statistical analyses are to evaluate safety and effectiveness of the BioWick  SureLock  implant 
in the reattachment of soft tissue to bone in rotator cuff repairs.   
A study center is defined as a hospital or medical office under the control and supervision of 
the Principal Investigator .   
 
16.2 Sample Size and Power  
The study is sized with respect to the primary one-year survivorship endpoint of the study. 
Assuming an observed one -year survivorship of 85 %, a total of 59 subjects is required  in 
order to estimate the true  survivorship within a 95% confidence interval with a half-width 
precision of 10.7%. This assumes a two -sided α=0.05 level of significance and that the data 
come from a binomial distribution. In order to account for a 15% lost- to-follow-up rate, the 
sample size will be upwardly adjusted to 7 1 total subjects.  
 
16.3 Analysis Populations  
The following analysis populations will be defined for  the study:   
 
ITT Population – The ITT population will consist of all subjects who have signed 
informed consent, been enrolled in the study, and have had a successful placement of 
the BioWick  SureLock  implant .  
 Safety Population – The safety  population will consist of all subjects who have 
signed informed consent, been rolled in the study and have had a procedure during which placement of the BioWick  SureLock  implant was attempted, whether or not 
placement was successful.     
The primary analysis population for all primary and secondary endpoints will be the ITT population.  The primary analysis population for safety will be the safety population.  
16.4 Analysis Subgroups  
Analysis subgroups may include age group.  
  
16.5 Statistical and Analytical Plans  
16.5.1 Primary Endpoint Analyses 
Implant survivorship for each subject will be determined by whether the subject undergoes a 
revision or reoperation of the study device. Survivorship will be assessed using a Kaplan -
BioWick® SureLock® Implant     
                          Protocol No.  CAY -001 
  
 
Confidential and Proprietary  
 24           Version 2.3 June 22, 2020  
 Meier analysis.   Data will be considered right- censored for all patients t hat do not have a 
device failure.   For patients lost- to-follow- up, their last available clinical visit will be used as 
the censored date.   For patients that die during the study, their death date will be used as the 
censored date.   The survivorship point estimate and 95% confidence interval about the point 
estimate will be calculated for the one-year primary endpoint.  
 
16.5.2 Secondary E ndpoint  Analyses 
Summary statistics (mean, standard deviation, sample size, median, minimum, and 
maximum) will be computed for all quantitative secondary effectiveness endpoints on the raw 
and change from baseline data by time point. Frequency counts and percentages will be reported for all categorical secondary effectiveness endpoints.  
 
16.6 Handling Missing Data  
In the statistical analysis of the primary effectiveness endp oint of the study, only subjects 
with evaluable endpoint will be used in the statistical analysis, i.e., a complete case analysis.   
 16.7 Interim Analysis  
Inter im analysis can be performed at any point during the duration of the study. 
 17. ADVERSE EVENTS  AND SERIOUS ADVERSE EVENTS  
Equipment, supplies, and properly skilled personnel must be available to treat any unexpected 
reaction.  
 
17.1 Safety  
Although major AEs are not anticipated, the investigator must proceed with utmost caution.   
 The AEs reported will be evaluated as to incidence, relationship to the time the device was used, how long the device had been in use, severity, and relationship to the medical device.  
The section on AEs will be tabulated by severity and by Investigator's assessment of the event's causative relation to treatment. AE counts by severity level (mild, moderate, and severe) will be tabulated.  
 
17.2 Definitions  
The term "adve rse event," as used by the Sponsor, is synonymous with the term "adverse 
experience," which is used by the FDA. 
 An adverse event  for a device is defined as “untoward medical occurrence”.  An adverse 
event is an untoward occurrence that is temporally associated with, but not necessarily related to or caused by, the use of the device If the untoward medical occurrence does not involve a subject, only occurrences related to the investigational device are included in the definition and handled by the Sponsor ’s adverse event system.  
BioWick® SureLock® Implant     
                          Protocol No.  CAY -001 
  
 
Confidential and Proprietary  
 25           Version 2.3 June 22, 2020  
  
A serious adverse event  is defined as any untoward medical occurrence that meets the 
following criteria:  
 1.   Results in death  (i.e., the AE actually causes or leads to death ) 
2. Is life -threatening (i.e., an AE that, in the opinion of the Investigator, places the 
subject at immediate risk of death ) 
3. Requires in-patient hospitalization or prolongs an existing hospitalization (i.e., the AE 
requires hospitalization lasting at least 24 hours or prolonged hospitalization beyond the expected amount of time; hospitalizations for scheduled medical or surgical procedures to conduct scheduled treatments or routine examinations of SAEs do not meet these criteria)  
4. Results in persistent or significant disability or incapacity (i.e., t he AE causes 
substantial disruption in the ability of the subject  to carry out normal activities)  
5. Is a congenital anomaly or birth defect in the infant/ newborn of a mother that has 
been exposed to the research compound  
6. Is considered by the Investigator to be significant medical event based on medical criteria (e.g., puts the subject  at risk or may require medical or surgical intervention to 
prevent one of the aforementioned results) 
  The seriousness must be evaluated independently from  the severity when documenting the 
AEs on the CRF . 
 Additionally, important medical events that may not result in death, be life threatening, or require hospitalization may be considered SAEs when, based on appropriate medical judgment, they may jeopardize the subject and may require medical or surgical intervention to prevent one of the outcomes listed above.    A life threatening adverse event  is any AE that places the subject at immediate risk of death 
from the event as it occurred .  A life -threatening e vent does not include an event that might 
have caused death had it occurred in a more severe form but that did not create an immediate risk of death as it actually occurred.  
 Hospitalization  is to be considered only as an overnight admission.  Hospitalization or 
prolongation of a hospitalization is a criterion for considering an AE to be serious.  In the absence of an AE, the participating investigator should not report hospitalization or prolongation of hospitalization on a form.   In addition, a hospitalization planned before the start of the study for a preexisting condition that has not worsened does not constitute an SAE (e.g. elective hospitalization after the procedure was performed and before study com pletion).  
 Disability  is defined as a su bstantial disruption in subject ’s ability to conduct normal life 
functions.  
BioWick® SureLock® Implant     
                          Protocol No.  CAY -001 
  
 
Confidential and Proprietary  
 26           Version 2.3 June 22, 2020  
 17.3 Reporting of Serious Adverse Events 
This section will address the reporting of the serious adverse ev ent to the Sponsor and/or their 
representatives. 
 
In the event that any SAEs occur during this study, the Investigator will notify the Sponsor or 
the Sponsor ’s safety representative via fax or phone immediately after becoming aware of the 
incident.  
 The Investigator will fax the SAE Report Form, and other doc umentation regarding the SAE 
to the Sponsor or the Sponsor ’s safety representative. The Investigator will promptly provide 
follow-up information requested by the Sponsor or the Sponsor ’s safety representative.  
 
17.4 Collecting, R ecording and Reporting  Adve rse Events 
Adverse events will be recorded from the time a subject has signed the I CF until the subject 
terminates from the study.  The Investigator is responsible for ensuring that all AEs are observed and reported during the study on the corresponding AE page of the CRF . 
  The Investigator will collect AE data at all stages of subject evaluation during the study. AEs 
will be recorded stating  the duration (i.e., onset and resolved dates) of the event , the intensity , 
the relationship to the device , the relationship to the surgical procedure , action taken, the 
outcome, the seriousness, regulatory criterion, if any, and the presumed association with the study. 
 
Note: The AE must be recorded on the AE page of the CRF .  Each AE should be marked 
appropriately on the AE page as to whether it is serious. An SAE must be reported to the 
Sponsor or the designated safety personnel as soon as possible after the Investigator has 
become aware of its occurrence.  
 
The causal relation between an AE and the study device will be determined by the investigator on the basis of his or her clinical judgment and the following definitions:  
• Definitely related: Event can be fully explained by administration of the study device. 
• Possibly related : Event may be explained by administration of the study device or by 
the subject’s clinical state or other agents/therapies.  
• Not related : Event can be fully explained by the subject’s clinical state or other 
agents/therapies.  
When assessing the relationship between the study device and an AE, the following should be 
considered:  
1. Temporal relationship between the administration of the study device and the AE; 
2. Biological plausibility of relationship ; 
3. Subject’s underlying clinical state ;  
BioWick® SureLock® Implant     
                          Protocol No.  CAY -001 
  
 
Confidential and Proprietary  
 27           Version 2.3 June 22, 2020  
 4. When applicable, whether the AE abates on discontinuation of the use of the study 
device.  
 SAEs that are not stud y related may nevertheless be considered by the participating 
investigator or the medical monitor (or designee) to be related to the conduct of the clinical study, i.e., to a subject's participation in the study. For example, a protocol- related SAE may 
be an event that is related to another non -test procedure required by the protocol. 
 The following definitions should be used when determining the severity of an AE.    
• Mild : The AE is noticeable to the subject but does not interfere with activity .   
• Moderate:  The AE interferes with routine activity but responds to symptomatic therapy 
or rest.  
• Severe:  The AE significantly limits the subject’s ability to perform activities despite 
symptomatic therapy . 
 18. STUDY SUSPENSION, TERMINATION, AND COMPLETION  
The Sponsor may suspend or terminate the study or part of the study at any time for any reason. If the investigator suspends or terminates the study, the investigator will promptly inform the Sponsor and the IRB and provide them with a detailed written explanation. Upon study completion, the investigator will provide the Sponsor, IRB, and regulatory agency with final reports and summaries as required by regulations. The investigator must submit a written report to the Sponsor and the IRB within three  months after the completion or 
termination of the study. Study termination and follow-up will be performed in compliance with the Sponsor ’s or designee’s standard procedures.  
 
18.1.1 Termination by the Sponsor  
The Sponsor may terminate the study, or the study site, at any time for any of the following 
reasons:  
1. Failure to enroll subjects  
2. Protocol violations  
3. Inaccurate or incomplete data  
4. Unsafe or unethical practices  
5. Questionable safety of the study device  
6. Suspected lack of appropriateness of the study device 
7. Administrative decision  
 
BioWick® SureLock® Implant     
                          Protocol No.  CAY -001 
  
 
Confidential and Proprietary  
 28           Version 2.3 June 22, 2020  
 18.1.2 Termination by the Investigator  
If the investigator terminates the study prematurely, the investigator must provide the IRB 
and the Sponsor with a written statement describing why the study was t erminated 
prematurely.  Prompt compliance with this requirement is essential so that the Sponsor may 
comply with its regulatory obligations.  
19. PROTOCOL AMENDMENTS  
Any change in the study plan requires a protocol amendment. An investigator must not make 
any changes to the study without IRB and Sponsor approval except when necessary to eliminate apparent immediate hazards to the subject s. A protocol change intended to 
eliminate an apparent immediate hazard to subjects  may be implemented immediately, but 
the ch ange must then be documented in an amendment, reported to the IRB and Sponsor 
within 5 working days, and submitted to the appropriate regulatory agency in the required time frame.    
 
20. QUALITY CONTROL AND ASSURANCE  
The Sponsor performs quality control and quality assurance checks on this clinical study in 
accordance with regulatory agency data integrity requirements and data management SOPs. Before enrolling any subjects in the study, the clinical study m onitor and the Investigator(s) 
will review the protocol, the IB, the CRF  instructions, the procedure for obtaining informed 
consent and the procedure for reporting AEs and SAEs.   
A qualified representative of the Sponsor monitors the conduct of the study by visiting the 
site, by contacting the  site by telephone, and sending emails.  During the visits, information 
recorded on the CRF s is verified against source documents.  The Sponsor ’s medical monitor 
or designee reviews the data for safety information.  The Sponsor ’s clinical data associates o r 
designees review the data for legibility, completeness, and logical consistency.    Additionally, the Sponsor ’s clinical data associates or designees use automated validation 
programs to help identify missing data, selected protocol violations, out-of- range data, and 
other data inconsistencies.  Access to the database shall be limited to appropriate personnel , 
per 21 CFR Part 11 compliance. 
 
21. DIRECT ACCESS, DATA HANDLING, AND RECORD- KEEPING  
21.1 Investigator 
The investigator will permit study -related monitoring, audits, IRB review, and regulatory 
inspections by providing direct access to original source data and documents. All subject information will be rec orded on source documents. The CRF s must be fully completed and 
include all required data for all subjec ts enrolled. All CRF  data must be submitted to the 
Sponsor throughout and at the end of the study.  
BioWick® SureLock® Implant     
                          Protocol No.  CAY -001 
  
 
Confidential and Proprietary  
 29           Version 2.3 June 22, 2020  
 21.2 Data Handling  
21.2.1 General Instructions for Data Collection   
 
Data will be collected on  CRFs .  Data will be collected either via paper or electronic CRFs. 
The Investigator will be responsible for the accuracy and completeness of the CRFs.  When 
submitted electronically, CRF completion will be tracked by the user name and password of 
the Investigator or designee.   This electronic data collection utility, an image archive, will be  
tested, validated, and documented prior to data collection and submission. All electronic 
systems are validated according to 21 CFR Part 11 and Good Clinical Practice standar ds. 
Appropriate audit trials exist on both the front and back end of the data management systems.  
Back -up files are maintained by the Sponsor in accordance with 21 CFR Part 11. Access to 
investigative folders will be controlled through user name and passwords, and each site will have access to their electronic folder throughout the course of the study. 
 
21.2.2 Data Submission  
 Completed Case Report Forms must be sent directly to the Sponsor for data load , validation 
and analysis. Every effort should be made to ensure data submission to the Sponsor within 30 days of visit completion. 
 
21.2.3 Quality Assurance of Data and Monitoring 
 Cayenne Medical Inc. or its designee will monitor and ensure this investigation is conducted in accordance with the signed Clinical Trial Agreement, the Investigational Plan, conditions imposed by the Institutional Review Boards and the requirements of Title 21, Code of Federal Regulations, Part 50, 54, 56, and 812.  The Sponsor will conduct a site initiation visit to ensure the investigators a nd staff have 
adequate time and resources to implement and follow the investigational plan, and ensure the investigators have access to the target patient population under study. Prior to initiation of the study, the investigator must have a fully executed Clinical Trial Agreement and IRB/EC 
approval of this investigational plan and informed consent.  During the investigation, the Sponsor will conduct periodic monitoring visits and maintain 
contact with the investigators and staff to monitor investigational plan compliance and evidence of s ubject related adverse events. The clinical study manager will report any non-
compliance with the signed Clinical Trial Agreement, investigational plan, applicable regulations, or any condition of approval imposed by the reviewing IRB/EC to the Sponsor.    CRFs  will be routinely reviewed by the Sponsor for completeness and accuracy and any 
evide nce of increased subject risk. When any discrepancies are identified, they will be 
addressed with the investigator or qualified designee.  
 
BioWick® SureLock® Implant     
                          Protocol No.  CAY -001 
  
 
Confidential and Proprietary  
 30           Version 2.3 June 22, 2020  
 21.2.4 Study Site Personnel Changes  
If an investigator retires, relocates, or otherwise withdraws from conducting the study, the 
investigator must notify the Sponsor to agree upon an acceptable storage solution. The IRB  
will be notified with the approp riate documentation. 
 
21.2.5 Adverse Event Reporting  
The investigator agrees to report all AEs to the Sponsor as described in the Adverse Events 
section .  Furthermore, the investigator is responsible for ensuring that any co- investigator or 
sub-investigator promp tly brings AEs to the attention of the investigator.  If applicable, the 
investigator also is responsible for informing the participating IRB  of any SAEs. 
 
21.2.6 Review of Source Records 
Source documents will be maintained on site and will consist of but not be limited to : 
handwritten progress notes, completed Sponsor provided template source documents, subject 
diary, dictated results, study logs, and study- specific site- generated documents. 
The investigator agrees that qualified representatives of the Sponsor an d regulatory agencies 
will have the right, both during and after this study, to conduct inspections and to audit and review medical records pertinent to the clinical study as permitted by the regulations.  Subjects will not be identified by name, and confi dentiality of information in medical records 
will be preserved. The confidentiality of the subject will be maintained unless disclosure is required by regulations. Accordingly, the following statements (or similar statement) will be included i n the informed consent document. 
 Representatives of regulatory agencies, IRBs, the Sponsor, and your personal physician may review your medical records and all information related to this study as permitted by law.  Identifying information will not appear on any record received by the Sponsor.  Subject identity will remain confidential unless d isclosure is required by law.    
  
21.2.7 Monitoring of the Study  
This study is monitored by a representative of the Sponsor .  Site visits may be made before 
the study begins, at regular intervals during the study, and at the study closeout.  
Communication by telephone and mail and e- mail may be used as needed to supplement site 
visits.  The investigator and study site  will permit monitoring, audits, IRB review, and 
regulatory inspection by providing authorized personnel from the Sponsor , its representatives, 
the IRB, the FDA and other appropriate regulatory agency direct access to all study data. Any party with direct access should take reasonable precautions to maintain the confidentiality of the study subjects and Cayenne Medical Inc.’s proprietary information. The purpose of the 
site visits is to verify the following:  
 1. Adherence to the protocol.  (The investigator should document and explain any deviation from the approved protocol.) 
BioWick® SureLock® Implant     
                          Protocol No.  CAY -001 
  
 
Confidential and Proprietary  
 31           Version 2.3 June 22, 2020  
 2. The completeness and accuracy of the CRF s. Adequate time and space for these visits 
should be allocated by the investigator.  
3. Compliance with regulations.  The verification will require comparison of the source 
documents to the CRF s. 
4. All subject records have complete, accurate and plausible ICFs and all study- specific 
logs. 
22. PUBLICATIONS POLICY  
The Sponsor will be responsible for determining when the study results should be published.  The Sponsor will work jointly with the investigators to publish information.  The investigator shall not submit a  publication to jour nals or professional societies without agreement and 
prior written approval of the Sponsor.    
 
BioWick® SureLock® Implant     
                          Protocol No.  CAY -001 
  
 
Confidential and Proprietary  
 32           Version 2.3 June 22, 2020  
   
REFERENCES  
 
 1. Patel, Manish. M.D.  Biomechanical Pullout Strength and Cyclic Testing of the 
SureLock™ All Suture Anchors .      
2. Barber et al. Cyclic Load Testing of Biodegradable Suture Anchors Containing 2 High-
Strength Sutures . Arthroscopy 2007 4:355-360 
 